相似文献
1
Update on treatments for dystonia.
Curr Neurol Neurosci Rep. 2014 Jun;14(6):454. doi: 10.1007/s11910-014-0454-8.
2
Treatment of dystonia.
Lancet Neurol. 2006 Oct;5(10):864-72. doi: 10.1016/S1474-4422(06)70574-9.
3
Medical treatment of dystonia.
Mov Disord. 2013 Jun 15;28(7):1001-12. doi: 10.1002/mds.25552.
4
Treatment of dystonia.
Parkinsonism Relat Disord. 2007;13 Suppl 3:S362-8. doi: 10.1016/S1353-8020(08)70031-2.
5
Preventing contractures [correction of contractions] in neuroleptic malignant syndrome and dystonia.
Am J Psychiatry. 1998 Sep;155(9):1298-9. doi: 10.1176/ajp.155.9.1298a.
6
Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis.
Dev Med Child Neurol. 2021 Sep;63(9):1038-1050. doi: 10.1111/dmcn.14874. Epub 2021 Mar 27.
7
Treatment of dystonia.
Neurotherapeutics. 2014 Jan;11(1):139-52. doi: 10.1007/s13311-013-0231-4.
8
Treatment of dystonia.
Expert Rev Neurother. 2006 Jun;6(6):863-86. doi: 10.1586/14737175.6.6.863.
9
The use of botulinum toxin in head and neck disorders.
Hosp Med. 2003 Aug;64(8):460-3. doi: 10.12968/hosp.2003.64.8.2259.
10
Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia.
J Neurol. 2002 Mar;249(3):300-4. doi: 10.1007/s004150200009.
引用本文的文献
1
Multitarget Multiscale Simulation for Pharmacological Treatment of Dystonia in Motor Cortex.
Front Pharmacol. 2016 Jun 14;7:157. doi: 10.3389/fphar.2016.00157. eCollection 2016.
2
Acrylamide inhibits nerve sprouting induced by botulinum toxin type A.
Neural Regen Res. 2014 Aug 15;9(16):1525-31. doi: 10.4103/1673-5374.139479.
本文引用的文献
1
Long-term intrathecal baclofen: outcomes after more than 10 years of treatment.
PM R. 2014 Jun;6(6):506-513.e1. doi: 10.1016/j.pmrj.2013.12.005. Epub 2013 Dec 17.
2
Pallidal deep brain stimulation for dystonia: a case series.
J Neurosurg Pediatr. 2013 Dec;12(6):582-7. doi: 10.3171/2013.8.PEDS13134. Epub 2013 Oct 4.
3
Medical treatment of dystonia.
Mov Disord. 2013 Jun 15;28(7):1001-12. doi: 10.1002/mds.25552.
4
Phenomenology and classification of dystonia: a consensus update.
Mov Disord. 2013 Jun 15;28(7):863-73. doi: 10.1002/mds.25475. Epub 2013 May 6.
5
Therapeutic potential of targeting metabotropic glutamate receptors for Parkinson's disease.
Neurodegener Dis Manag. 2012 Apr 1;2(2):221-232. doi: 10.2217/nmt.12.6.
6
History, applications, and mechanisms of deep brain stimulation.
JAMA Neurol. 2013 Feb;70(2):163-71. doi: 10.1001/2013.jamaneurol.45.
7
Long-term efficacy and safety of botulinum toxin injections in dystonia.
Toxins (Basel). 2013 Feb 4;5(2):249-66. doi: 10.3390/toxins5020249.
8
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Toxicon. 2013 Jun 1;67:94-114. doi: 10.1016/j.toxicon.2012.12.004. Epub 2013 Feb 4.
9
Setting realistic expectations for DBS in dystonia.
Lancet Neurol. 2012 Dec;11(12):1014-5. doi: 10.1016/S1474-4422(12)70263-6. Epub 2012 Nov 1.
10
Shorter disease duration correlates with improved long-term deep brain stimulation outcomes in young-onset DYT1 dystonia.
Neurosurgery. 2012 Aug;71(2):325-30. doi: 10.1227/NEU.0b013e318258e21b.
Zotero 插件